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BACKGROUND: Epidemiological studies have suggested a protective effect of cyclooxygenase (COX)-inhibiting non-steroidal anti-
inflammatory drugs in breast cancer risk and disease progression. We performed a systematic review to evaluate the frequency of
COX-2 expression in normal breast epithelium, ductal carcinoma in situ of breast (DCIS), DCIS-adjoining invasive breast cancer,
microinvasive carcinoma of the breast (MICB) and invasive breast cancer.
METHODS: Literature searches were carried out on MEDLINE, EMBASE and Web of Science from their commencement
until September 2010. Primary studies examining COX-2 expression by immunohistochemistry methodology were included.
Meta-analyses were carried out using random effects models for individual study estimates of COX-2 expression and pooled to give
an overall estimate.
RESULTS: The pooled prevalences (95% confidence intervals) of COX-2 expressions were 53% (44–61) in DCIS studies and
42% (36–49) in the invasive breast cancer studies. There were too few studies involving normal breast epithelium, DCIS-adjoining
invasive breast cancer and MICB to conduct meta-analyses.
CONCLUSION: The findings from our meta-analyses have shown similar COX-2 expression in DCIS and invasive breast cancer. This
may suggest the involvement of COX-2 in early carcinogenesis. Further studies of COX-2 expression in DCIS are required to
investigate the use of COX-2 as a potential drug target for prevention of disease progression in DCIS.
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The cyclooxygenase (COX) enzyme system consists of two forms:
COX-1 and COX-2. COX-1 is constitutively expressed, whereas
COX-2 expression is induced by cytokines, growth factors and
oncogenes (Howe, 2007). There is considerable evidence to suggest
a role for COX-2 in carcinogenesis. The prostaglandins produced
by COX-2 are involved in key processes in cancer development
including proliferation, mutagenesis, resistance to apoptosis,
angiogenesis, immune suppression and invasion (Singh and Lucci,
2002; Harris, 2009). It has been proposed that COX-2 expression in
ductal carcinoma in situ (DCIS) has a crucial role in the
development of breast cancer, with the ability of DCIS to progress
to invasive breast cancer being dependent on the COX-2 enzyme’s
role in the destruction of the basal membrane and in the formation
of new blood vessels allowing tumour growth (Imada et al, 2006).
COX-2 expression in invasive breast cancer tissue has been widely
documented and expression has been associated with poorer
prognostic parameters and disease progression (Singh-Ranger
et al, 2008). The use of COX inhibitors has been associated with
reduced breast cancer risk (Takkouche et al, 2008). In addition,
several studies have suggested a reduced risk of recurrence and
death from breast cancer in women who have used non-steroidal
anti-inflammatory drugs (NSAIDs) after diagnosis (Blair et al,
2007; Kwan et al, 2007; Holmes et al, 2010). However, these studies
have not examined tumour COX-2 expression in relation to disease
progression.
To further explore the role that COX-2 expression may have in
the development and progression of breast cancer, we undertook a
systematic review to determine the frequency of COX-2 expression
in the continuum from normal breast epithelium to invasive
carcinoma of the breast.
METHODOLOGY
Literature search
Systematic searches were conducted using three electronic
databases (MEDLINE, EMBASE and Web of Science) from their
commencement to September 2010. Identified keywords and
medical subject heading (MeSH) terms for COX-2 were combined
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susing the ‘OR’ operator. This was repeated for normal breast
epithelium, DCIS, microinvasive carcinoma of the breast (MICB)
and invasive breast cancer. Results for COX-2 and either normal
breast epithelium, DCIS, MICB and invasive breast cancer
were then combined using the ‘AND’ operator (Supplementary
Resource 1 online). The search strategy was limited to human
studies and where publications were available in English.
Duplicate articles were removed and titles, and abstracts if
necessary, were screened to exclude irrelevant articles. Where an
abstract was not available or the article’s significance was unclear,
the full article was examined. Articles retrieved for DCIS (DCIS-
adjoining invasive breast cancer) and MICB were independently
screened for relevance by three reviewers (CH, LM and JG) and
discrepancies were reviewed by a fourth person (MC). Articles
retrieved for normal breast epithelium and invasive breast cancer
were independently screened by two reviewers (JG and either MC,
CH, LM or colleagues) and discrepancies were discussed as a group
(MC, CH, LM and JG). References of all included articles were
screened to identify other potentially relevant publications (JG).
Articles were assessed according to predefined inclusion and
exclusion criteria. For inclusion, studies were required to be
primary investigative research, have used an immunohistochem-
ical (IHC) method for the assessment of COX-2 expression and
have reported the proportion (%) of breast tissue samples
exhibiting COX-2 expression or data from which this proportion
could be calculated. As monoclonal antibodies are more specific,
have a higher homogeneity and therefore provide more repro-
ducible results than polyclonal antibodies, only studies using
monoclonal anti-COX-2 antibodies were included (Abcam plc,
1998–2010). Assessment of staining in IHC studies is subjective
therefore only studies where COX-2 expression was evaluated
using at least two independent assessors were included. Articles
that included samples from men or from women with a previous
history of DCIS or invasive breast cancer were excluded. Studies of
either normal breast epithelium, DCIS or DCIS adjacent to invasive
cancer and MICB that contained fewer than 10 samples were
excluded. As a greater number of studies were published on
invasive breast cancer, studies that contained fewer than 100
samples were excluded. For studies in which the sample source was
reported on repeatedly, only the largest set of results was used. Of
note, a variety of definitions have been applied to MICB in relation
to the extent of stromal invasion (Bianchi and Vezzosi, 2008). We
included any definition of MICB in this review.
Data extraction
Data extraction was performed by the principal reviewer (JG). Data
extraction forms were designed to record information on the year
of publication, study location, source of data, number of samples,
time period over which samples were obtained and the method of
evaluation of COX-2 expression.
COX-2 evaluation
The evaluation method for COX-2 expression differed between
studies. Several studies provided an immunoreactive score (IRS),
which was calculated by multiplying a staining intensity score
with a score for quantity of staining. Other studies only assessed
the quantity of COX-2 staining. Only lesions reported to express
COX-2 (by either of these methods) at a moderate or strong
level were defined as COX-2 positive within this meta-analysis.
A further description of COX-2 evaluation in the studies is
provided in Supplementary Resource 2 online.
Statistical analysis
We used random effects models to account for both within-study
and between-study variance. Individual study estimates (ES) for
COX-2 expression from each study were pooled to give an overall
estimate. All estimates were calculated with 95% confidence
intervals (CIs). The degree of heterogeneity among studies was
investigated for each tissue group using w
2-tests (Q statistic) and
the I-squared measure (I
2 statistic). Forest plots were used to
depict the results of pooled analyses. All statistical analyses were
carried out using the ‘meta’ package in STATA (SE version 11.0;
StataCorp 2005, College Station, TX, USA).
RESULTS
Normal breast epithelium
The search identified 833 studies (Medline n¼47, Embase n¼105
and Web of Science n¼681). A total of 800 articles were screened
after removal of duplicates. A total of 24 potentially relevant
papers were fully screened. Additionally, one paper was included
from the DCIS search results. In all, 23 studies were excluded as the
samples were taken adjacent to breast cancer or from patients who
previously had breast cancer (n¼11), the proportion (%) of COX-2
expression was not reported or could not be calculated (n¼9),
the study did not use monoclonal anti-COX-2 antibodies (n¼2) or
did not report independent evaluation of COX-2 staining by two
assessors (n¼1). Two studies, one Korean and the other from the
United States of America, met the inclusion criteria and meta-
analysis of the data was not possible. Both studies were hospital
based and samples were extracted from tissue archives. Similar
COX-2 expression evaluation methods were reported. The
prevalences of COX-2 expression in these two studies were 6.7
and 100% (Table 1). The time period for which breast tissue was
obtained was not specified in either study, and only one study
reported that the samples were from reduction mammoplasty
(Zhao et al, 2008).
DCIS
The search identified 303 studies (Medline n¼40, Embase n¼61
and Web of Science n¼202). A total of 275 articles were screened
after removal of duplicates. A total of 36 potentially relevant
studies were fully screened. In all, 31 studies were excluded as the
proportion (%) of COX-2 expression in DCIS was not reported or
could not be calculated (n¼13), the sample size was below 10
(n¼6), the tissue source was used in a larger study (n¼9), the
study did not state use of monoclonal anti-COX-2 antibodies (n¼2)
or the study did not report independent evaluation of COX-2
staining by two assessors (n¼1). Five studies met the criteria for
inclusion and data were extracted to conduct a meta-analysis. Two
studies were undertaken in the United States of America, one in
Italy, one in Spain and one in Korea (Table 1). One study was
population based (Kerlikowske et al, 2010) and the remaining
studies used samples obtained from hospital archives. The earliest
samples included were obtained between 1983 and 1994 in
Kerlikowske et al’s study and the most recent samples included
were obtained between 1998 and 2003 in a study by Perrone et al
(2005). The random effects pooled estimate of COX-2 positivity
was 53% (95% CI, 44–61; P¼0.04) with evidence of moderate
heterogeneity I
2¼60.1% (Figure 1).
DCIS adjacent to invasive cancer
Five of the 36 studies that examined DCIS investigated DCIS
adjacent to invasive cancer. Four of these were excluded as the
study did not use monoclonal anti-COX-2 antibodies (n¼1) or did
not report independent evaluation by two assessors (n¼3).
Therefore only one hospital-based study (undertaken in Germany)
met the inclusion criteria. The time period over which samples
were obtained was not specified. The frequency of COX-2
expression in this study was 55.2% (Table 1).
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The search identified 18 studies (Medline n¼1, Embase n¼1 and
Web of Science n¼16). After removal of duplicates, 16 articles
were screened. Additionally, one paper was included from the
DCIS search results. Of these, four potentially relevant studies were
fully screened. Three studies were excluded as COX-2 expression
was not examined (n¼2) or the study did not state use of
monoclonal anti-COX-2 antibodies (n¼1). One study (undertaken
in Spain) met the inclusion criteria. This was a hospital-based
study and samples were extracted from tissue archives. The MICB
samples were retrieved between 1985 and 2003. The frequency of
COX-2 expression was 74.0% (Table 1).
Invasive breast cancer
The search identified 5204 studies (Medline n¼728, Embase
n¼1142 and Web of Science n¼3334). After removal of
duplicates, 4914 articles were screened. Of these, 154 potentially
relevant papers were fully screened. In all, 142 studies were
excluded as the proportion (%) of COX-2 expression in invasive
breast cancer was not reported (n¼50), the sample size was below
100 (n¼33), the study used cell lines or animal models (n¼22),
the study included previous/adjoining cancers or other tissue
samples (n¼13), the study did not report independent evaluation
by two assessors (n¼7), the paper was a review (n¼6), male
patients were included in the study (n¼5), no translation was
available for the paper (n¼2), the study did not use monoclonal
anti-COX-2 antibodies (n¼2), the tissue source was used in a
larger study (n¼1) or the paper had missing data (n¼1). A total
of 12 studies met the criteria for inclusion and data were extracted
to conduct a meta-analysis. Four studies were undertaken in
Germany, two in Finland, one from each of Austria, Japan, Poland,
Sweden, the United Kingdom and the United States of America
(Table 1). One study was population based (Ristimaki et al, 2002)
and the remaining studies used samples obtained from hospital
archives. The earliest samples were obtained between 1977 and
1990 in the study by Gunnarsson et al (2006) and the most recent
samples were obtained between 1993 and 2001 in the study by
Yamamoto et al (2008). The individual study estimates were widely
dispersed about the random effects pooled estimate; 42% (95% CI,
36–49; Po0.001) with evidence of high heterogeneity I
2¼92.0%
(Figure 2).
DISCUSSION
The aim of this systematic review was to determine the frequency
of COX-2 expression in the continuum from normal breast
epithelium to invasive carcinoma of the breast. A robust estimate
could not be obtained for normal breast epithelium, DCIS adjacent
to invasive breast cancer or MICB as so few studies have been
performed. COX-2 expression was common in DCIS and invasive
breast cancer (pooled estimates in the studies of 53% and 42%
respectively), and there was no significant difference in prevalence
of COX-2 expression between these lesions.
To our knowledge this is the largest, and first systematic, review
of publications reporting COX-2 expression in invasive breast
cancer. A review by Denkert et al (2004), which did not include a
meta-analysis, investigated COX-2 expression in 2392 primary
Note: weights are from random effects
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Figure 1 Forest plots of COX-2 expression in DCIS.
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Figure 2 Forest plots of COX-2 expression in invasive breast cancer.
Table 1 Characteristics of the included studies for normal breast
epithelium, DCIS, DCIS-adjoining invasive breast cancer, MICB and invasive
breast cancer
Study Location
Number of
samples
included (n)
COX-2
positive
(n)
COX-2
positive
(%)
Normal breast
Cho et al (2006) Korea 15 1 6.7
Zhao et al (2008) USA 19 19 100.0
DCIS
Perrone et al (2005) Italy 49 31 63.3
Cho et al (2006) Korea 30 19 63.3
Kulkarni et al (2008) USA 59 27 45.8
de la Torre et al (2010) Spain 52 28 53.8
Kerlikowske et al (2010) USA 279 124 44.4
DCIS-adjoining invasive breast cancer
Leo et al (2006) Germany 29 16 55.2
MICB
de la Torre et al (2010) Spain 40 30 74.0
Invasive breast cancer
Ristimaki et al (2002) Finland 1576 589 37.4
Denkert et al (2003) Germany 221 80 36.2
Spizzo et al (2003) Austria 212 103 48.6
Wulfing et al (2003) Germany 192 78 40.6
Witton et al (2004) UK 179 38 21.2
Sivula et al (2005) Finland 231 70 30.3
Surowiak et al (2005) Poland 104 46 44.2
Gunnarsson et al (2006) Sweden 284 108 38.0
Schmitz et al (2006) Germany 113 49 43.4
Yamamoto et al (2008) Japan 171 97 56.7
Zhao et al (2008) USA 108 46 42.6
Darb-Esfahani et al
(2009)
Germany 101 74 73.3
Abbreviations: COX2¼cyclooxygenase 2; DCIS¼ductal carcinoma in situ of breast;
MCIB¼microinvasive carcinoma of the breast.
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included 12 studies that reported on COX-2 expression in 3492
invasive breast cancer samples. The overall COX-2 expression from
our meta-analysis in invasive breast cancer was consistent with
findings of the Denkert review. In addition, our review has been
the first to review COX-2 expression in DCIS samples separate to
invasive breast cancer. We can report the prevalence of COX-2
expression in DCIS to be similar to that of invasive breast cancer.
It is believed that most invasive breast carcinoma originates from
DCIS and that the two coexist in B50% of cases (Boland et al,
2004). Only one study (Leo et al, 2006) met our inclusion criteria in
DCIS-adjoining invasive breast cancer. The frequency of COX-2
expression reported in this study (study estimate 55.2%) was
similar to that of DCIS or invasive breast cancer in our meta-
analyses. One study (de la Torre et al, 2010) met the inclusion
criteria in MICB. This study reported COX-2 expression in 74% of
samples. However, the paucity of studies in this tissue type has
prevented any COX-2 frequency to be established. The two studies
of normal breast epithelium included in our review provided very
different estimates of the prevalence of COX-2 expression in
normal tissue, so we cannot determine whether COX-2 expression
occurs more or less frequently in invasive or in-situ breast cancer
than in normal breast tissue.
We adopted a number of approaches to increase the robustness
of the results of this review/meta-analysis. Studies with fewer than
10 normal breast epithelium, DCIS or MICB samples and 100
invasive breast cancer samples were excluded, only samples which
expressed COX-2 at a moderate or higher level (reported by two
observers) were considered positive and only studies that used
monoclonal anti-COX-2 antibodies were included in an attempt to
limit between-study variation. However, high heterogeneity was
still evident despite our strict exclusion criteria. Between-study
variance may have resulted from the diverse populations included
in the studies. In addition, differences in the evaluation of COX-2
expression and cut-off marks for COX-2 positivity may have
caused variation in individual study estimates. The evaluation of
COX-2 expression by quantity of staining alone may allow more
tissue to be regarded as positively stained, as this does not
incorporate the intensity of staining like in other evaluation
methods. Finally, several of the studies included were small and
only investigated archived tissue from single centres. Larger
population-based studies would provide more robust findings.
Several studies have reported on COX-2 expression and disease
recurrence in invasive breast cancer and have shown elevated
levels of COX-2 expression to be associated with a more aggressive
cancer and decreased survival (Ristimaki et al, 2002; Haffty et al,
2008). Further, three observational studies have shown a reduced
risk of disease progression in breast cancer survivors who use
NSAIDs (Blair et al, 2007; Kwan et al, 2007; Holmes et al, 2010).
However, few studies have provided follow-up information on the
relationship between COX-2 positivity in DCIS and disease
progression after treatment, and none have explored whether
NSAID use modulates the risk of progression (Kulkarni et al, 2008;
Kerlikowske et al, 2010).
This review has shown high (and similar) levels of COX-2
expression in DCIS and invasive breast cancer. This suggests that
COX-2 is involved in early breast cancer carcinogenesis. Further
investigation of the importance of COX-2 expression and inhibi-
tion in the progression of DCIS is warranted.
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